EXAFS characterization of oxaliplatin anticancer drug and its degradation in chloride media.

Oxaliplatin is a second-generation platinum-based anticancer drug. Its degradation is studied in solution, in the presence of chloride ions (in neutral or acidic media) in excess. In both cases the degradation product precipitates immediately. The EXAFS spectra of these products show that they are identical. EXAFS modeling and refinement of the first coordination sphere shows that two light atoms are replaced by two chloride ions. The complete refinement of the local structure is possible by studying the multiple-scattering signal. The results show that the main multiple-scattering contribution is due to the binding oxalato group and that the degradation product is [Cl(2)-(diaminocyclohexane)-Pt(II)]

Identification of a BRCA2-Specific modifier locus at 6p24 related to breast cancer risk

Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80-0.90, P = 3.9×10−8). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.Peer reviewe

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10-8, HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10-8, HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4×10-8, HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific associat

Nanocatalyseurs Cu100-xPdx pour la réduction électrochimique du CO2

International audienc

Copper-Palladium Nanoelectrocatalysts for Carbon Dioxide Reduction, International Symposium on Electrocatalysis

International audienc

Electrochemical oxidation of urea on nickel-rhodium nanoparticles/carbon composites

International audienc

Metal-Assisted Chemical Etching for the Direct Synthesis of Bimetallic Cu-Pd Nanoparticles on Silicon

An original study is presented for the synthesis of Cu100-xPdx nanoparticles directly on silicon by Metal Assisted Chemical Etching (MACE). CuPd is chosen as a representative bimetallic system on account of its interest and potential applications in catalysis and electrocatalysis, among others. The proposed methodology allows precise control of the nanoparticle bimetallic composition and structure. Thus, we demonstrate that Cu100-xPdx solid solutions and phase-separated nanoparticles can be synthesized at will by simply changing the deposition conditions. In-depth physical characterization of the synthesized material (structure, morphology, composition, oxidation state and d-band center position) is carried out by XRD, SEM-EDX and XPS. Finally, band bending simulations at the nanoscale in combination with electrochemical measurements help to interpret some of the peculiarities of the Pd, Cu and CuxPd100-x deposits. The new method can be easily implemented, used for various silicon substrate geometries and extended to any bimetallic system whose metals are suitable for MACE of silicon

Photoelectrocatalytic conversion of urea under solar illumination using Ni decorated Ti-Fe2O3 electrodes

International audienceTo reduce the energy cost and environmental impact of biological nitrogen removal in wastewater treatment plants, it would be advantageous to treat urea contained in urine at the source. In this perspective, FTO/Ti-Fe2O3 (nanorods) photoelectrodes decorated with Ni as catalyst are developed and tested for urea photoelectrocatalytic oxidation under solar illumination. Gains up to 0.50 V in oxidation onset potential vs. metallic Ni are obtained thanks to a Ni photoelectrodeposition method. In situ transmission measurements (based on NiOOH light absorption) during electrochemical cycling allowed to evaluate the state of active Ni sites and confirmed that urea oxidation mechanism is of EC type. Photoelectrolyses give faradaic efficiencies of 10–18% and 9-35% for N2 and O2 formation, respectively. A significant and unexpected NO2− production (∼65%) is detected indicating another or incomplete reaction pathway. The photoelectrocatalytic removal of nitrogen from urea solutions is demonstrated but requires catalysts with higher selectivity towards N2